CoChat
Cited by 208

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Tetrahydroaminoacridine–Lecithin Combination Treatment in Patients with Intermediate-Stage Alzheimer's Disease: Results of a Canadian Double-Blind, Crossover, Multicenter Study

Open access
Gauthier, Serge, Bouchard, Rémi, Lamontagne, Albert, Bailey, Peter, Bergman, Howard, Ratner, Jack, Tesfaye, Yoseph, Saint-Martin, Monique, Bacher, Yves, Carrier, Louise, Charbonneau, Roland, Clarfield, A. Mark, Collier, Brian, Dastoor, Dolly, Gauthier, Louise, Germain, Marcel, Kissel, Catherine, Krieger, Monique, Kushnir, Seymour, Masson, Hélène, Morin, Jacques, Nair, Vasavan, Neirinck, Leonard, Suissa, Samy · 1990 · New England Journal of Medicine

Abstract

We studied the efficacy and safety of oral tetrahydroaminoacridine (THA) combined with lecithin in 52 patients with Alzheimer's disease. The maximal tolerated dose of THA (up to 100 mg per day) was determined during an eight-week titration period, after which the tolerated dose of THA or placebo was given during two sequential randomized periods of treatment lasting eight weeks each. Highly purified lecithin (4.7 g per day) was administered during all phases of the study. Efficacy was expressed in terms of scores on the Mini-Mental State (MMS) test, the modified MMS test, the Hierarchic Dementia Scale, the Rapid Disability Rating Scale-II, and the behavioral scale of Reisberg et al. Safety was assessed by careful clinical monitoring as well as serial measurements of liver aminotransferases. Forty-six patients completed the titration period, and 39 completed the double-blind period, during which only the MMS score showed a small but significant increase (P less than 0.05) after four weeks of treatment with THA. Autonomic side effects of THA were common but mild. Reversible elevations of serum aspartate and alanine aminotransferase levels to three or more times the upper limit of normal occurred in 17 percent of patients; most of the patients affected were women. A liver biopsy performed in one patient showed resolving focal liver-cell necrosis. These studies fail to demonstrate a significant clinical benefit of THA given orally in a maximal dose of 100 mg per day over a period of eight weeks in combination with lecithin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199005033221804

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 208

Metadata

Authors
Gauthier, S., Bouchard, R., Lamontagne, A., Bailey, P., Bergman, H., Ratner, J., Tesfaye, Y., Saint-Martin, M., Bacher, Y., Carrier, L., Charbonneau, R., Clarfield, A. M., Collier, B., Dastoor, D., Gauthier, L., Germain, M., Kissel, C., Krieger, M., Kushnir, S., Masson, H., Morin, J., Nair, V., Neirinck, L., & Suissa, S.
Venue
New England Journal of Medicine
Published
1990-05-03
Volume
322
Issue
18
Pages
1272-1276
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2020961258
Cited by
208
References
1
FWCI
18.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tetrahydroaminoacridine–Lecithin Combination Treatment in Patients with Intermediate-Stage Alzheimer's Disease: Results of a Canadian Double-Blind, Crossover, Multicenter Study. https://app.cochat.ai/papers/10.1056/nejm199005033221804
The paper
Gauthier, S., Bouchard, R., Lamontagne, A., Bailey, P., Bergman, H., Ratner, J., Tesfaye, Y., Saint-Martin, M., Bacher, Y., Carrier, L., Charbonneau, R., Clarfield, A. M., Collier, B., Dastoor, D., Gauthier, L., Germain, M., Kissel, C., Krieger, M., Kushnir, S., . . . Suissa, S. (1990). Tetrahydroaminoacridine–Lecithin Combination Treatment in Patients with Intermediate-Stage Alzheimer's Disease: Results of a Canadian Double-Blind, Crossover, Multicenter Study. New England Journal of Medicine. https://doi.org/10.1056/nejm199005033221804

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.